Drugs / GEMTUZUMAB OZOGAMICIN
GEMTUZUMAB OZOGAMICIN
also known as
CDP-771 · CMA-676 · CMC-676 · Gemtuzumab ozogamicin (genetical recombination) · Gemtuzumab ozogamicin recombinant · Gemtuzumab ozogamicina · Gemtuzumab ozogamicine · L01XC05 · +2 more
targets CD33
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05199051 Background | Jun 2023 → Jul 2028 expected | acute myeloid leukemia | Centre Antoine Lacassagne | Active not recruiting | No outcome recorded |
Press releases naming this drug 4 releases
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GEMTUZUMAB OZOGAMICIN | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201506 ↗ |
| Known as | CDP-771 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201506 ↗ |
| Known as | CMA-676 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201506 ↗ |
| Known as | CMC-676 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201506 ↗ |
| Known as | Gemtuzumab ozogamicin (genetical recombination) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201506 ↗ |
| Known as | Gemtuzumab ozogamicin recombinant | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201506 ↗ |
| Known as | Gemtuzumab ozogamicina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201506 ↗ |
| Known as | Gemtuzumab ozogamicine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05199051 ↗ |
| Known as | L01XC05 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201506 ↗ |
| Known as | Mylotarg | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201506 ↗ |
| Known as | WAY-CMA-676 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201506 ↗ |
| Route | Intravenous | “3mg/m2/day (5mg max), IV, 2h of infusion.” NCT05199051 ↗ |
| Target | CD33 | “Myeloid cell surface antigen CD33 binding agent” CHEMBL1201506 ↗ |